Related Experiment Video
Updated: Dec 19, 2025
Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
Published on: September 17, 2015
Inotropic agents in cardiogenic shock
Eftihia Polyzogopoulou1, Angelos Arfaras-Melainis2,3, Vasiliki Bistola2
1Emergency Medicine Department, Attikon University Hospital.
Insights
This review provides a guide for using inotropes and vasopressors in cardiogenic shock management. It proposes a clinical algorithm to aid in the initial treatment of this complex condition.
Area of Science:
- Cardiology
- Pharmacology
- Critical Care Medicine
Background:
- Cardiogenic shock is a complex condition requiring inotropic therapy.
- Current clinical trials focus on pharmacologic treatments, but lack a decision-making algorithm for inotropes.
Purpose of the Study:
- To review cardiogenic shock pathophysiology and the pharmacodynamics of inotropes and vasopressors.
- To summarize recent guidelines and propose a management algorithm for inotropic and vasopressor use in cardiogenic shock.
Main Methods:
- Review of existing literature on cardiogenic shock, inotropes, and vasopressors.
- Analysis of agent indications, adverse effects, and special considerations.
- Development of a clinical algorithm based on shock stage.
Main Results:
- Inotropes are central to cardiogenic shock treatment.
- An algorithm for inotropes and vasopressors use and combinations is proposed.
- The algorithm serves as an initial management guide during etiological investigation.
Conclusions:
- A structured approach to inotropic and vasopressor therapy is crucial for cardiogenic shock.
- The proposed algorithm can guide initial management decisions.
- Further research may refine treatment strategies for cardiogenic shock.
Purpose Of Review:
Cardiogenic shock is a multifactorial and diverse entity in which inotropes are the cornerstone therapy. Although published clinical trials have focused on pharmacologic treatment of cardiogenic shock, there is lack of an established and widely accepted decision-making algorithm on the use of inotropic agents in cardiogenic shock.
Recent Findings:
The current review incorporates cardiogenic shock pathophysiology, inotropes and vasopressors pharmacodynamics. It emphasizes on each agent's indications, potential adverse effects, highlights special considerations and fsummarizes the recent guidelines.
Summary:
Finally, proposes an algorithm of inotropes and vasopressors use and their potential combinations based on the clinical stage of cardiogenic shock. This algorithm can be used as a guide during the initial management of cardiogenic shock while underlying cause investigation is underway.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: β-Blockers
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers